Summary
The company kept its full-year guidance unchanged at operating revenue of JPY 3,980M and operating income of JPY 165M. Management expects to book milestone and upfront payments in 2H. 1H operating loss was JPY -338M, which implies 2H operating income of JPY +503M is needed to meet guidance (our estimate). The first checkpoint in 3Q results is whether the upfront payments underpinning the plan were booked in July–September. The JPY 200M upfront payment from Hisamitsu Pharmaceutical has already been disclosed for 4Q recognition, so it will contribute to full-year results rather than 3Q. For the underlying revenue base, we will track K-CAB® prescription growth in Korea, tegoprazan's US development progress and trends in animal health products. Another focus is whether the company can contain losses while absorbing higher costs, particularly R&D.
Key Points for Next Quarter
| Key Points & Focus | Implications |
|---|---|
Revenue Progress9M cumulative operating revenue vs. full-year guidance; timing of milestone and upfront payment recognition | 1H achievement rate was 36.6%, implying JPY 2,525M of operating revenue is needed in 2H (our estimate). This exceeds the prior-year 2H actual of JPY 2,444M, so 3Q revenue recognition warrants close attention. |
Royalty BaseK-CAB® prescription growth; expansion of tegoprazan's markets and approvals | 1H prescription sales in Korea reached KRW 120B (+15.4% YoY). Sustained growth at this pace would lift recurring revenue. We will look for incremental contributions from the 20 launch markets and US development progress. |
Cost StructureYoY trends in R&D expenses and other SG&A | 1H R&D expenses were JPY 861M (+10.1%) and other SG&A JPY 592M (+6.9%). Comparing against the prior-year standalone 3Q operating loss of JPY -154M (our estimate) will show how well the cost increase is being absorbed. |
Recurring Profit and Tax BurdenNon-operating items (FX gains/losses) and income tax levels | 1H benefited from a JPY 36M FX gain, but income taxes of JPY 140M pushed the interim net loss to JPY -466M. We will monitor the tax burden against the full-year net loss guidance of JPY -63M. |
Balance Sheet and Business DevelopmentCash and deposits, loan repayments, progress on new deal structures | At 1H-end, cash and deposits stood at JPY 4,575M and the equity ratio was 70.6%. We will check how the agreements with Lazarus portfolio companies, which include equity consideration, are reflected, including in investment securities. |
Key Issues from Previous Results (FY12/2026 2Q Results)
1H operating revenue was JPY 1,455M (-5.2% YoY), with an operating loss of JPY -338M. Management said results were "broadly in line with the initial plan" and maintained full-year guidance on the assumption of milestone and upfront payments in 2H. Tegoprazan prescriptions grew in Korea, and a third-party allotment to HK inno.N strengthened the balance sheet. The central question for 3Q is how much of the 2H-weighted revenue profile can actually be delivered.
1. Progress on 2H Upfront Payments and the Path to Full-Year Guidance
- Prior Quarter: 1H operating revenue was JPY 1,455M, a 36.6% achievement rate against full-year guidance of JPY 3,980M (our estimate). The company noted that the upfront payments assumed in guidance were not booked in 1H and are expected in 2H.
- This Quarter: We will check whether milestone or upfront payments were booked in July–September. If not, we want to gauge the degree of 4Q concentration and the rationale for maintaining guidance.
- Key Metrics: 9M cumulative operating revenue vs. full-year guidance (prior-year 9M: JPY 2,311M). Standalone 3Q operating income/loss against the JPY +503M of operating income required in 2H (our estimate).
2. Tegoprazan Royalty Growth and US Expansion
- Prior Quarter: 1H prescription sales in Korea were KRW 120B (+15.4% YoY), ranking first with a 15% market share. In April 2026, the drug ranked No. 1 across all products in monthly outpatient prescription sales for the first time.
- This Quarter: Tegoprazan is marketed in 20 countries, and we will monitor progress in markets under regulatory review, such as Australia. In the US, the TRIUMpH-EE trial has shown superiority data, and the key question is whether management addresses a regulatory filing.
- Key Metrics: YoY growth in K-CAB® prescriptions and the number of launch markets as shown in the earnings materials. Comparison with prior-year standalone 3Q operating revenue of JPY 776M (our estimate).
3. Balancing R&D Investment and Cost Control
- Prior Quarter: Operating expenses were JPY 1,794M (+3.9% YoY). Cost of operating revenue fell to JPY 339M (-12.7%), while R&D expenses rose to JPY 861M (+10.1%).
- This Quarter: We will assess the administrative efficiency gains from the January 2026 absorption-type merger of TMRC. We will also track costs related to FIMECS' targeted protein degrader research and joint research with RIKEN.
- Key Metrics: YoY change in 9M cumulative R&D expenses and other SG&A. Standalone 3Q operating income/loss vs. JPY -154M in the prior-year period (our estimate).
4. Drivers of the Gap Between Recurring Profit and Net Income
- Prior Quarter: The recurring loss was JPY -326M, but income taxes of JPY 140M widened the interim net loss to JPY -466M. Below the operating line, the prior-year FX loss of JPY 104M swung to an FX gain of JPY 36M.
- This Quarter: Tax expense is calculated using the estimated effective tax rate, but the earnings release does not explain why a tax burden arises despite the loss. We will review the breakdown of extraordinary items and income taxes, as well as FX volatility linked to foreign currency-denominated revenue.
- Key Metrics: 9M cumulative income taxes (prior-year 9M: JPY 142M), FX gains/losses, and the gap between recurring profit and quarterly net income attributable to owners of parent company.
5. Deploying the Balance Sheet and New Business Development Structures
- Prior Quarter: The third-party allotment to HK inno.N and other issuances raised capital stock and capital surplus by a combined JPY 1,423M. Cash and deposits stood at JPY 4,575M, and long-term borrowings fell by JPY 256M on repayments.
- This Quarter: The agreements with Giathera and Giovel include partial equity consideration, designed to capture both milestones and equity returns. We want to see partnering progress on out-licensing candidates such as the ghrelin receptor agonist.
- Key Metrics: Cash and deposits at 3Q-end, investment securities (JPY 664M at 1H-end), borrowings, and goodwill (JPY 3,560M at 1H-end).
Key Timely Disclosures During the Period
- 2026/10/21Receipt of Upfront Payment Upon Initiation of Phase II Trial of Novel Sodium Channel Blocker - Receipt of a JPY 200M upfront payment for the compound out-licensed to Hisamitsu Pharmaceutical has been confirmed and is scheduled to be booked as operating revenue in 4Q (October–December). The payment is already factored into this fiscal year's guidance.
- 2026/09/02Notice of Allowance in Korea for TRPV4 Antagonist - Following allowances in China, Japan, Europe and the US, the compound has now secured allowances from all five major patent offices (IP5). This strengthens the IP foundation for out-licensing negotiations.
Previous Quarter Results (FY12/2026 2Q Actual)
The company is a drug discovery business that out-licenses compounds from its research to pharmaceutical companies, earning revenue from upfront payments, milestones and royalties. Its main revenue sources are tegoprazan (K-CAB®) royalties via HK inno.N and animal health products out-licensed to Elanco. In 1H, revenue declined because no upfront payments were booked, and higher R&D expenses widened the operating loss. The company expects to book upfront payments in 2H and has maintained its full-year profit plan.
| Item | Amount | YoY | vs. Company Plan | Notes |
|---|---|---|---|---|
| Revenue (Operating Revenue) | JPY 1,455M | -5.2% | - | No 1H guidance disclosed. 36.6% achievement rate vs. full-year guidance of JPY 3,980M (our estimate) |
| Operating Income | JPY -338M | - | - | Prior-year period: JPY -190M. R&D expenses up +10.1% |
| Recurring Profit | JPY -326M | - | - | Prior-year period: JPY -291M. FX gain of JPY 36M booked |
| Net Income (Interim Net Income Attributable to Owners of Parent Company) | JPY -466M | - | - | No extraordinary items. Income taxes of JPY 140M |
| EPS | JPY -18.10 | - | - | Prior-year period: JPY -15.49. Full-year forecast: JPY -2.58 |
Guidance Achievement Rate (Recurring Profit Basis): Not calculable (1H cumulative recurring loss of JPY -326M vs. full-year guidance of JPY 86M) (prior-year period: -). For reference, the operating revenue achievement rate vs. full-year guidance was 36.6% (prior-year period: 38.6% vs. full-year actual; both our estimates)
ENVALITH, INC. ("ENVALITH") provides exclusive research coverage services to domestic and international institutional investors, as well as domestic individual investors, with the objective of contributing to the development of global and Japanese capital markets by providing information necessary for considering investments in Japanese listed companies.
- Purpose and Disclaimer Regarding Investment Decisions
This report has been prepared solely for informational purposes and does not constitute a solicitation to acquire, sell, or hold securities or any other financial products. Furthermore, this report does not constitute specific investment, financial, or tax advice. Any opinions, judgments, or recommendations contained herein are not intended to induce investment activities. Please be advised that all investment decisions must be made based on the investor's own responsibility and judgment, and ENVALITH and subject company shall not be involved in any such investment decisions.
- Information Sources, Accuracy, and Disclaimer of Warranty
This report has been prepared based on a formal request from the subject company, utilizing information provided by and interviews conducted with said company. By using this report, you are deemed to have agreed to the following: 1. Information Sources: This report is prepared on the assumption that the publicly available information and information disclosed by the subject company and provided during interviews is true and reliable. ENVALITH has not independently verified or validated the veracity of such information. 2. Accuracy: The interpretations, analyses, and hypotheses or conclusions based thereon contained in this report are independently derived by ENVALITH using its own perspectives and analytical methods based on the information mentioned in the preceding paragraph. 3. Disclaimer of Warranty: In the event that there are errors or omissions in the information disclosed by the subject company, ENVALITH and subject company shall not be held liable for any inaccuracies in this report resulting therefrom. ENVALITH and subject company make no warranties, whether express or implied, regarding the accuracy, safety, validity, completeness, or any other aspect of this report, nor regarding the past or future performance of the subject company.
- Limitation of Liability
ENVALITH and subject company shall not be liable for any costs, damages, or losses (including direct, indirect, incidental, consequential, or punitive damages) arising from the use of this report or the information obtained therefrom. Users of this report acknowledge and agree that such use is at their own risk.
- Potential Conflicts of Interest
ENVALITH may have, or may have in the future, business relationships with the subject company. Accordingly, investors should be aware that conflicts of interest may exist that could affect the objectivity of this report.
- No Obligation to Change or Update Content
The contents and opinions in this report, as well as the information upon which it is based, are current as of the date of preparation and are subject to change without notice. Please be advised that ENVALITH is under no obligation to update the contents of this report, and investors must verify the timeliness of the information on their own.
- Governing Language
This report is prepared in Japanese, English, and Chinese. In the event of any discrepancy or difference in interpretation between the language versions, the Japanese version shall be treated as the original and shall prevail.
- Copyright
All rights (including copyrights) relating to this report belong to ENVALITH. Any reproduction, redistribution, or other use of all or part of this report without the prior written permission of ENVALITH is strictly prohibited.
- Use for Other Investment Products
Except where ENVALITH has provided prior written approval, the use of this report and the trademarks or trade names of ENVALITH or the subject company in connection with the information distribution, transaction, sales promotion, or advertising of any investment products (including derivatives, structured products, investment trusts, or investment assets whose price, return, or performance is based on or linked to this report) is strictly prohibited.